RESEARCH ARTICLE

Urinary proteomics links keratan sulfate degradation and lysosomal enzymes to early type 1 diabetes

Julie A. D. Van1,2*, Sergi Clotet-Freixas3, Anne-Christin Hauschild3,4, Ihor Batruch5, Igor Jurisica3,6,7, Yesmino Elia3, Farid H. Mahmud8, Etienne Schectt8, Eleftherios P. Diamandis5,9, James W. Scholey1,2,10, Ana Konvalinka1,2,10

1 Institute of Medical Science, University of Toronto, Toronto, Canada, 2 Toronto General Hospital Research Institute, University Health Network, Toronto, Canada, 3 Krembil Research Institute, University Health Network, Toronto, Canada, 4 Department of Mathematics & Computer Science, University of Marburg, Marburg, Germany, 5 Department of Laboratory Medicine and Pathobiology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 6 Department of Computer Science, University of Toronto, Toronto, Canada, 7 Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, 8 Hospital for Sick Children, Toronto, Ontario, Canada, 9 Department of Clinical Biochemistry, University Health Network, University of Toronto, Toronto, Canada, 10 Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada

* julie.van@mail.utoronto.ca

Abstract

Diabetes is the leading cause of end-stage renal disease worldwide. Our understanding of the early kidney response to chronic hyperglycemia remains incomplete. To address this, we first investigated the urinary proteomes of otherwise healthy youths with and without type 1 diabetes and subsequently examined the enriched pathways that might be dysregulated in early disease using systems biology approaches. This cross-sectional study included two separate cohorts for the discovery (N = 30) and internal validation (N = 30) of differentially excreted proteins. Discovery proteomics was performed on a Q Exactive Plus hybrid quadrupole-orbitrap mass spectrometer. We then searched the pathDIP, KEGG, and Reactome databases to identify enriched pathways in early diabetes; the Integrated Interactions Database to retrieve protein-protein interaction data; and the PubMed database to compare fold changes of our signature proteins with those published in similarly designed studies. Proteins were selected for internal validation based on pathway enrichment and availability of commercial enzyme-linked immunosorbent assay kits. Of the 2451 proteins identified, 576 were quantified in all samples from the discovery cohort; 34 comprised the urinary signature for early diabetes after Benjamini-Hochberg adjustment (Q < 0.05). The top pathways associated with this signature included lysosome, glycosaminoglycan degradation, and innate immune system (Q < 0.01). Notably, all enzymes involved in keratan sulfate degradation were significantly elevated in urines from youths with diabetes (fold change > 1.6). Increased urinary excretion of monocyte differentiation antigen CD14, hexosaminidase A, and lumican was also observed in the validation cohort (P < 0.05). Twenty-one proteins from our signature have been reported elsewhere as potential mediators of early diabetes. In this study, we identified a urinary proteomic signature for early type 1 diabetes, of which lysosomal enzymes were major constituents. Our findings highlight novel
Introduction

Diabetes is the leading cause of end-stage renal disease worldwide. In the clinic, an early sign of diabetic kidney injury is microalbuminuria, which has traditionally been regarded as a defining point in the course of disease [1, 2]. Recent evidence however has demonstrated that kidney function may deteriorate in the absence of proteinuria [3, 4] and that microalbuminuria may revert back to normal urinary albumin excretion rates over time [5–7]. These findings undermine the clinical utility of microalbuminuria as a reliable predictor of disease. Therefore, important changes occur in the diabetic kidney long before clinical manifestations of injury.

Our modern understanding of early diabetic kidney injury was initially constructed using histopathological examinations from the 1980s [8, 9]. Notable features of the diabetic kidney under the microscope include mesangial expansion, glomerular basement membrane thickening, and podocyte loss, which are often present long before the onset of microalbuminuria or decline in kidney function [10]. Building on this framework has been difficult, as kidney biopsies carry significant morbidity and are typically performed in cases of advanced or atypical diabetic kidney disease. Accordingly, major gaps in knowledge continue to exist and present as barriers to improving care and delivering targeted treatments.

Urinary proteomics could offer novel insights into the pathogenesis of early diabetic kidney injury for three key reasons [11]. First, urine represents a suitable and non-invasive alternative to biopsies because it is directly produced by the kidneys. At this early stage of injury, the permselective barrier of the kidney remains largely intact, preventing the filtration of large macromolecules (>20 kDa) into urine. Proteins detected in urine are thus more likely to originate from the kidneys, ureter, and bladder than from the circulation. Second, this approach enables the broad characterization of thousands of proteins from relatively low volumes of urine [12]. Advances in mass spectrometry techniques have also significantly improved in accuracy and sensitivity in recent years. Third, proteomic analyses produce large datasets that can be further dissected in silico to extract information on tissue origins, protein-protein networks, and involvement in pathways and reactions. Therefore, to examine the early renal response to chronic hyperglycemia, we first conducted a proteomic investigation into the urines from otherwise healthy youths with and without type 1 diabetes and subsequently applied systems biology approaches to examine the early, dysregulated pathways that are over-represented by the differentially excreted proteins.

Materials and methods

Study design and population

Our examination of the early kidney response to chronic hyperglycemia relies on the careful selection of an appropriate study population. Complete details of the study criteria have been described elsewhere in a peptidomic analysis [13]. Briefly, all participants were 19 years of age or younger; free of significant comorbidity including hypertension and proteinuria; and not using corticosteroid, anti-hypertensive, or anti-inflammatory medications. Youths with type 1 diabetes were considered to be in the earliest and uncomplicated stage of the natural history of diabetic kidney disease. They were recruited and initially screen from multiple diabetes clinics.
in the Greater Toronto Area; while youths without diabetes were either family members of those with type 1 diabetes or healthy volunteers recruited at the Hospital for Sick Children and Toronto General Hospital.

This cross-sectional study includes a discovery cohort \( (N = 30) \) and an internal validation cohort \( (N = 30) \). The primary exposure variable is diabetes status. Each participant provided a single urine sample for the study. To determine the appropriate cohort size, we performed power calculations using the following parameters in G\(^\text{Power} \) software: study power of 80\%, the independent two-sample \( t \)-test and Benjamini-Hochberg (BH) correction with a false detection rate (FDR) of 0.0001, and an effect size \( d \) of 2. In each cohort, thirty samples were collected from 15 otherwise healthy youths with type 1 diabetes and 15 non-diabetic peers. Thus, a total of 60 second-morning midstream urine samples was collected from 60 youths.

Clinical characteristics of both cohorts at time of urine collection are summarized in Table 1. Groups in the discovery cohort were matched according to age \( (\pm 1 \text{ year}) \) and sex; groups in the validation cohort were matched according to age \( (\pm 1 \text{ year}) \) only. The research ethics boards at the Hospital for Sick Children and Mount Sinai Hospital approved this study. In accordance with the Declaration of Helsinki, written informed consent was obtained from the legal guardians, next-of-kin, or caretakers of youths under the age of 16 years, while said youths provided assent. Youths aged 16 and older with capacity to understand the study information provided complete written and informed consent to participate in the study.

**Collection, handling, and storage of urines**

Second-morning, midstream urines were collected, handled, and stored in accordance with the Standard Protocol for Urine Collection and Storage created by the Human Kidney and Urine Proteome Project (HKUPP) and the Human Proteome Organization (HUPO) [14]. Following collection, all fresh urine samples were kept at 4°C until further processing. All urine samples were centrifuged at 1000 g for 10 minutes to remove intact cells and debris. This initial processing step was completed within 3 hours of urine collection to obviate the need for urine preservatives. Samples were de-identified and randomized so that investigators were blinded to experimental groups during processing.

**Discovery proteomics**

The workflow is summarized in Fig 1. After thawing, urines were vortexed and centrifuged at 1000 g for 10 minutes. To account for differences in hydration, we used volumes containing 90 \( \mu \text{mol} \) of urinary creatinine. Ammonium bicarbonate was added to increase alkalinity of samples (to a pH of 8) for later steps. We passed the urines through Vivaspin Centrifugal

---

Table 1. Clinical characteristics of both cohorts at time of urine collection.

| Clinical Characteristics | Discovery Cohort | Validation Cohort |
|--------------------------|------------------|------------------|
|                         | Youths without T1D \( (N = 15) \) | Youths with T1D \( (N = 15) \) | Youths without T1D \( (N = 15) \) | Youths with T1D \( (N = 15) \) |
| Age \( \text{years} \)   | 16.0 ± 1.8       | 15.7 ± 1.8       | 16.0 ± 1.2       | 16.5 ± 1.1       |
| Sex \( \text{females/males} \) | 6 / 9           | 6 / 9           | 5 / 10           | 6 / 9           |
| HbA1c \( \% \)   | n.m.             | 8.9 ± 1.5       | 5.1 ± 0.3        | 9.1 ± 1.6       |
| Diabetes duration \( \text{years} \) | n.a.           | 9.7 ± 2.9       | n.a.             | 10.4 ± 2.9       |
| ACR \( \text{mg/mmol} \) | n.m.             | 0.8 ± 0.5       | 0.6 ± 0.2        | 1.1 ± 1.1       |
| eGFR \( \text{ml/min/1.73m}^2 \) | 118 ± 18        | 102 ± 15        | 115 ± 24         |

Data is presented as mean ± standard deviation, except for sex (frequency). P values are shown between youths with and without type 1 diabetes (T1D). HbA1c, glycated hemoglobin; ACR, albumin/creatinine ratio; eGFR, estimated glomerular filtration rate; n.m., not measured; n.a., not applicable.

https://doi.org/10.1371/journal.pone.0233639.t001
Concentrators (VivaProducts) with 10-kDa cut-off membranes to isolate the protein content. (The filtrate was analysed using urinary peptidomics [13].) Protein concentrations were measured in the retentate using the bicinchoninic acid (BCA) assay such that protein quantification was normalized by total protein amount. A total of 200 μg of protein was denatured with urea, reduced with dithiothreitol, alkylated with iodoacetamide, and digested overnight with trypsin. Proteolysis was terminated after 16 hours on the next day using formic acid. Peptides were subsequently speed-vacuumed to remove excess water content and reduce volumes to below 200 μL.

Next, we performed strong cation exchange high-performance liquid chromatography (SCX-HPLC). Peptides were loaded onto a PolySULFOETHYL ATM column (The Nest Group Incorporation) containing a hydrophilic, anionic polymer (poly-2-sulfoethyl aspartamide). We created a 60-minute fractionation method with a linear gradient of 0.26 M formic acid in 5% acetonitrile as the running buffer and 1 M ammonium formate added as the elution buffer. We combined 12 of the 26 fractions, which covered the largest area on the chromatogram, into 3 pooled fractions. Further desalting and concentration were carried out with Agilent Technologies Bond Elut OMIX C18 tips with a bed mass of 8 μg. Peptides were then eluted in 5 μL of 65% acetonitrile and diluted with 60 μL of 0.1% formic acid in pure mass spectrometry-grade water; 18 μL of which was injected into the mass spectrometer (~2 μg of total protein per injection).

Overall, three fractions per youth were analyzed over a 60-minute gradient on a Thermo Scientific EASY-nLC1000 system, coupled to a Thermo Scientific Q Exactive Plus hybrid quadrupole-orbitrap mass spectrometer using nano-electrospray ionization. They were first loaded onto a 3.3 cm C18 pre-analytical column (IntegraFrit capillary, New Objective; inner diameter of 150 μm; 5 μm bead size; Agilent Pursuit C18, Agilent Technologies) and then a C18 resolving analytical column with dimensions 15 cm x 75 μm ID (PicoTip emitter, 8 μm Fig 1. Workflow for the discovery-based urinary proteomics.

https://doi.org/10.1371/journal.pone.0233639.g001
tip, New Objective Agilent Pursuit C18, 3 μm bead size). Data-dependent acquisition mode was used with full MS1 scans from 400–1500 m/z with a resolution of 70,000 and MS2 scans of the top 12 parent ions with a resolution of 17,500. Xcalibur software (v. 3.0.63; Thermo Fisher Scientific) was utilized to generate RAW files of each run. Mass spectrometry data have been deposited onto the ProteomeXchange Consortium via the PRIDE [15] partner repository with the dataset identifier PXD017213 (http://www.ebi.ac.uk/pride/archive/login).

Mass spectrometry analysis

Raw data were analyzed by MaxQuant software (version 1.5.3.8) and were searched against the human Uniprot FASTA database (July 2016 version containing 42158 protein entries) using the built-in Andromeda search engine [16]. The false discovery rate was set to 1% using a revert database for both proteins and peptides with a minimum length of six amino acids. The digestion mode was specific for trypsin/P with a maximum of 2 missed cleavages. Cysteine carboxymethylation was selected as a fixed modification; while methionine oxidation, proline oxidation, and N-terminal acetylation as variable modifications. Potential contaminants were allowed in the search and manually removed post hoc. The initial peptide tolerance was set to 20 ppm against a small ‘human-first-search’ database. The main search peptide mass tolerance was 4.5 ppm, and the fragment mass tolerance was set to 0.5 Da. Matching between runs was selected. Stabilized label-free quantification (LFQ) of proteins derived from extracted ion current information from razor and unique peptides with a minimum ratio count of 2. The fast LFQ option was selected with a minimum ratio count of 2, minimum of 3 neighbours, and average of 6 neighbours.

We analyzed the proteomic data using Perseus software (version 1.5.5.3) [17]. Reverse hits were first filtered out; non-human contaminants were manually checked and removed. We then examined the subset of proteins identified in 100% of urine samples to focus on the most robust changes in the proteome. Fast LFQ intensities were log(x) transformed to approximate a normal distribution. Differential LFQ intensities between groups were then determined using the independent t-test (P < 0.05), followed by BH adjustment (Q < 0.05).

Bioinformatic analyses

The Human Protein Atlas was searched to determine tissue origins of urinary proteins [18]. Plots were created with R software. For the heatmap analysis, we converted peptide intensities into z-scores and performed Euclidean hierarchical clustering. We also searched the pathDIP tool (version 4.0.21.2; http://ophid.utoronto.ca/pathDIP/) [19] using all sources, KEGG BRITE and Pathway Mapper tools (version 4.1; https://www.genome.jp/kegg/) [20], and Reactome (version 71; https://reactome.org/) [21, 22]. The Integrated Interactions Database (IID, version 2018–11; http://iid.ophid.utoronto.ca/) was used to retrieve experimentally-proven and predicted protein-protein interaction data [23].

Enzyme-Linked Immunosorbent Assay (ELISA)

Urinary protein concentrations were measured in duplicate with commercial human ELISA kits: from R&D Systems, cluster of differentiation 14 (DY383), lumican (DY2846), and vascular cell adhesion molecule 1 (DY809); and from Raybiotech, hexosaminidase A (ELH-HEXA-1). We also purchased and used the R&D Systems Ancillary Reagent Kit 2 (DY008) in conjunction with the aforementioned R&D Systems Duoset ELISA kits. Frozen urine samples were thawed and kept at 4˚C until further processing, centrifuged at 2000 g for 5 minutes, and diluted in the appropriate reagent diluent supplied by the kit. All plates were read by spectrophotometry at 450 nm, and label subtraction was carried out at 540 nm using EnVision 2103
Multilabel Reader (Perkin Elmer, Waltham, MA, USA). Urinary concentrations were determined from standard curves according to specific kit instructions and were adjusted for urinary creatinine concentrations. Differential peptide excretion was determined using the Mann-Whitney test ($P < 0.05$) in the validation cohort.

**Results**

**Characterization of urinary proteome of early type 1 diabetes**

A summary of the proteomic workflow is illustrated in Fig 1. Overall, we identified 2451 urinary proteins from 30 otherwise healthy youths with and without type 1 diabetes (Fig 2A). A total of 2313 proteins was quantified (S1 Table): 1960 in youths with type 1 diabetes, 2079 in youths without type 1 diabetes, and 1726 in both groups (Fig 2B). There were 234 proteins that exclusively derived from the diabetic group; however, none were quantified in more than 3 urine samples. Similarly, the 353 proteins that were only found in the non-diabetic group were quantified in a small minority of samples. To examine the most robust changes in the urinary proteome, we focused on a subset of 576 proteins (S2 Table), which were quantified in every urine sample. According to the Human Protein Atlas [18], more than 80% of proteins can be

---

![Fig 2. Characterization of the urinary proteomes of 15 youths with type 1 diabetes and 15 non-diabetic peers.](https://doi.org/10.1371/journal.pone.0233639.g002)
found in the kidney in an enriched/elevated (5%) or non-specific (79%) pattern (Fig 2C). We then compared protein intensities between groups and identified 123 differentially excreted proteins ($P < 0.05$) (Fig 2D). Thirty-four proteins remained significant following BH adjustment ($Q < 0.05$) (Table 2). The heatmap analysis of these 34 proteins highlighted two distinct clusters of youths based on diabetes status, although segregation was incomplete (Fig 2E). Urinary excretion of the signature proteins appears to be coordinated, as the majority of signature proteins were strongly correlated with one another ($|r| > 0.6$) (S1 Fig).

**Lysosomal enzymes dominate urinary protein signature of early diabetes**

We first used the pathDIP tool [19] (version 4.0.21.2) as a broad survey of the enriched pathways associated with the 34 signature proteins (S3 Table). Even though the tool collates data from 24 sources, pathways from KEGG and Reactome databases were most commonly represented in the enriched set (BH-adjusted, $Q < 0.05$).

We then searched the KEGG Pathway and BRITE Mapper tools [20] to identify all of the pathways and functional hierarchies associated with the top 34 proteins (S4 Table). Five proteins were not identified in the KEGG Orthology. Of the 29 proteins searched, 23 were classified as enzymes (Fig 3A). Fifteen enzymes were mapped to the lysosome (Fig 3B), which included five members of the cathepsin protease family (CTSA, CTSB, CTSC, CTSD, and CTSH), five glycosidases (tissue alpha-L-fucosidase, FUCA1; beta-galactosidase, GLB1; beta-hexosaminidase subunit alpha and beta, HEXA and HEXB; lysosomal alpha-mannosidase, MAN2B1; and alpha-N-acetylgalactosaminidase, NAGA), three sulfatases (arylsulfatase B, ARSB; N-acetylgalactosamine-6-sulfatase, GALNS; and N-acetylgalactosamine-6-sulfatase, GNS), and acid ceramidase (ASAH1). Other notable pathways included metabolism, glycosaminoglycan degradation, other glycan degradation, glycosphingolipid biosynthesis (ganglio and globo series), and apoptosis.

We also searched the Reactome pathway database (version 71) [21, 22] to replicate the KEGG findings and to focus on specific pathways and reactions. Two proteins, carboxypeptidase Q (CPQ) and NAGA, were not identified in the Reactome database and were thus not included in this analysis (S5 Table). A total of 154 pathways were associated with at least one protein. Seventy-nine pathways were significant enriched ($P < 0.05$); twenty-five remained statistically significant after BH correction ($Q < 0.01$) (Fig 3C). The top three pathways were neutrophil degranulation, innate immune system, and keratan sulfate degradation.

By searching both databases, we were able to highlight several similarities. Notably, the lysosomal enzymes are involved in glycosaminoglycan metabolism, glycosphingolipid metabolism, and the immune system, namely neutrophil degranulation. Using the Integrated Interactions Database [23], we demonstrated that these signature proteins may interact with one another within these pathways (Fig 3D). Interestingly, all enzymes involved in keratan sulfate degradation (ie., GALNS, GLB1, GNS, HEXA, and HEXB) were elevated in urines from youths with type 1 diabetes, compared to non-diabetic youths (Fig 3E). Furthermore, urinary excretion of these five enzymes significantly correlated with one another with Pearson coefficients ranging between 0.61 to 0.80 ($P \leq 0.0002$) (S2A Fig). In addition, urinary excretion of lumican, a core protein of keratan sulfate proteoglycan, was higher in diabetes with a fold change of 2.16 ($Q = 0.0445$) (Table 2). Lumican was most strongly correlated with GNS ($r = 0.63$, $P = 0.0002$), GALNS ($r = 0.54$, $P = 0.0004$), and HEXA ($r = 0.52$, $P = 0.0030$) (S2A Fig).

**Internal validation**

We selected four proteins for internal validation in a second, independent cohort of youths with and without type 1 diabetes on the basis of: 1) availability of a commercial enzyme-linked
immunosorbent assay kit; 2) a role in keratan sulfate biology and degradation; and 3) a role in innate immunity. Increased urinary excretion of CD14 ($P = 0.0057$), HEXA ($P < 0.0001$), and lumican ($P = 0.0014$) was replicated in a second cohort of youths with and without type 1 diabetes (Fig 4A). Urinary excretion of VCAM-1 was also higher in diabetes, but it did not reach statistical significance ($P = 0.0675$). These four proteins were significantly correlated with one another with Pearson coefficients ranging between 0.47 and 0.81 ($P \leq 0.0083$) (S2B Fig). The fold changes and Pearson coefficients were similar to those observed in the discovery cohort (Table 2, S2C Fig).

Table 2. Summary of urinary proteins significantly altered in early type 1 diabetes.

| Protein Name (Gene) | UniProt Number | Fold Change | $P$  | $Q$  | Fraction of Unique Peptides | Sequence Coverage (%) |
|---------------------|----------------|-------------|------|------|----------------------------|----------------------|
| Aminoacylase-1 (ACY1) | Q03154         | 0.44        | 0.0000 | 0.0047 | 23/23                      | 67                   |
| Serine hydroyxymethyltransferase (SHMT1) | P34896         | 0.48        | 0.0028 | 0.0471 | 19/19                      | 55                   |
| Metalloprotease inhibitor 2 (TIMP2) | P16035         | 0.52        | 0.0007 | 0.0214 | 8/8                        | 36                   |
| Triosephosphate isomerase (TP1) | P60174         | 0.53        | 0.0026 | 0.0451 | 23/23                      | 89                   |
| Follistatin-related protein 1 (FSTL1) | Q12841         | 0.55        | 0.0008 | 0.0242 | 13/13                      | 44                   |
| Retinal dehydrogenase 1 (ALDH1A1) | P00352         | 0.58        | 0.0024 | 0.0437 | 23/25                      | 65                   |
| Nucleobindin-1 (NUCB1) | Q02818         | 0.60        | 0.0007 | 0.0224 | 34/34                      | 63                   |
| Acid ceramidase (ASAH1) | Q13510         | 1.58        | 0.0008 | 0.0237 | 24/24                      | 58                   |
| Beta-hexosaminidase subunit alpha (HEXA) | P06865         | 1.64        | 0.0016 | 0.0338 | 22/22                      | 41                   |
| Cathepsin D (CTSD) | P07339         | 1.82        | 0.0003 | 0.0131 | 29/29                      | 66                   |
| Arylsulfatase B (ARSB) | P15848         | 1.85        | 0.0000 | 0.0047 | 15/15                      | 31                   |
| Tissue alpha-L-fucosidase (FUCA1) | P04066         | 1.89        | 0.0019 | 0.0362 | 12/12                      | 31                   |
| Ribonuclease T2 (RNASET2) | O00584         | 1.91        | 0.0009 | 0.0237 | 13/13                      | 45                   |
| Alpha-1-antichymotrypsin (SERPINA3) | P01011         | 1.94        | 0.0009 | 0.0232 | 29/29                      | 61                   |
| Cathepsin H (CTSH) | P09668         | 1.97        | 0.0009 | 0.0235 | 16/16                      | 61                   |
| N-acetylglucosamine-6-sulfatase (GNS) | P15586         | 1.97        | 0.0003 | 0.0132 | 23/23                      | 41                   |
| Beta-hexosaminidase subunit beta (HEXB) | P07686         | 2.00        | 0.0001 | 0.0076 | 27/27                      | 49                   |
| Beta-galactosidase (GLB1) | P16278         | 2.00        | 0.0003 | 0.0143 | 27/27                      | 40                   |
| Ig kappa chain V-III region VG (IGKV3-11) | P04433         | 2.03        | 0.0010 | 0.0247 | 4/4                        | 57                   |
| Lyosomal protective protein (CTSA) | P10619         | 2.06        | 0.0001 | 0.0079 | 17/17                      | 40                   |
| Cathepsin B (CTSB) | P07858         | 2.15        | 0.0010 | 0.0238 | 21/21                      | 62                   |
| Lumican (LUM) | P51884         | 2.16        | 0.0025 | 0.0445 | 20/20                      | 45                   |
| Ig kappa chain V-I region WEA (IGKV1-17) | P01610         | 2.18        | 0.0006 | 0.0194 | 2/4                        | 37                   |
| Gamma-glutamyl hydrolase (GGH) | Q92820         | 2.21        | 0.0003 | 0.0139 | 19/19                      | 46                   |
| Ig kappa chain V-II region TEW (IGKV2D-28) | P01617         | 2.26        | 0.0016 | 0.0341 | 1/3                        | 39                   |
| N-acetylgalactosamine-6-sulfatase (GALNS) | P34059         | 2.26        | 0.0001 | 0.0055 | 23/23                      | 57                   |
| Epididymis-specific alpha-mannosidase (MAN2B2) | Q9Y2E5         | 2.32        | 0.0003 | 0.0124 | 32/32                      | 38                   |
| Monocyte differentiation antigen CD14 | P08571         | 2.33        | 0.0017 | 0.0328 | 21/21                      | 71                   |
| Carboxypeptidase Q (CPQ) | Q9Y646         | 2.33        | 0.0000 | 0.0032 | 19/19                      | 49                   |
| Vascular cell adhesion protein 1 (VCAM1) | P19320         | 2.49        | 0.0012 | 0.0257 | 23/23                      | 39                   |
| Dipeptidyl peptidase 1 (CTSC) | P53634         | 2.52        | 0.0000 | 0.0042 | 21/21                      | 45                   |
| Alpha-N-acetylgalactosaminidase (NAGA) | P17050         | 3.00        | 0.0000 | 0.0047 | 16/16                      | 39                   |
| Lyosomal alpha-mannosidase (MAN2B1) | O00754         | 3.65        | 0.0000 | 0.0003 | 30/30                      | 39                   |
| Leucine-rich alpha-2-glycoprotein (LRG1) | P02750         | 4.58        | 0.0000 | 0.0048 | 19/19                      | 57                   |

Fold change represents the ratio of the median label-free quantification (LFQ) protein intensity of the diabetic group to the median value of the non-diabetic group. $P$ values were determined using the Student t-test and then corrected with the Benjamini-Hochberg adjustment ($Q$). The number of unique peptides for each protein is shown as a fraction over the total number of peptides.

https://doi.org/10.1371/journal.pone.0233639.t002
We next examined whether these four proteins may be associated with an early pro-inflammatory signal in diabetes. In a previous study [13], we had selected eight urinary cytokines and chemokines and demonstrated that interleukin (IL)-6, IL-8, IL-18, interferon gamma-induced...
protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein 1-beta (MIP1B) could be measured in urine from youths with and without diabetes. Although urinary excretion of MCP-1 did not appear to be significantly different between groups [13], it correlated with urinary excretion of CD14 ($r = 0.38, P = 0.0376$), HEXA ($r = 0.43, P = 0.0180$), and lumican ($r = 0.47, P = 0.0094$) (Fig 4B; S2B Fig). Interestingly, HEXA also correlated with IL-18 ($r = 0.54, P = 0.0020$) and IP-10 ($r = 0.54, P = 0.0067$) (Fig 4C). A complete summary of correlations between protein and cytokine/chemokine can be found in S2B Fig.

Comparison with other studies

As an additional validation step, we compared our findings to other similarly designed studies. More specifically, we searched and reviewed the PubMed database and PRIDE Archive repository for studies that examined the urinary proteomics of otherwise healthy populations with diabetes using the following search terms and their variations: “urine”, “proteomic”, “diabetes”, “early”, and “human”. To ensure that urinary protein signatures of each study reflected the early mechanisms of injury or renal compensation, we excluded studies that included

![Fig 4. Internal validation of four proteins in a second, independent cohort.](https://doi.org/10.1371/journal.pone.0233639.g004)
individuals with clinical diabetic kidney disease (e.g., microalbuminuria, proteinuria, decline in glomerular filtration rate) and other complications (e.g., cardiovascular disease, hypertension). A total of three relevant studies met these criteria [24–26].

We then retrieved and collated publicly available data to define the urinary protein signature for each of the three studies. For two studies [24, 25], we applied the same criteria as our study for significant differential excretion on the basis of BH adjustment ($Q < 0.05$). For one study [26], we included all 45 proteins identified from the 61 spots that had an absolute fold change above 1.6 and a $P$ value below 0.06 after hierarchical clustering to identify the most radically different subset of youths with very early type 1 diabetes (duration of less than one year) from youths without diabetes. We found that 21 proteins from our signature were also differentially excreted in at least one of the three other proteomics studies of early diabetes (Fig 5A; S6 Table). Notably, three proteins (CPQ, CTSB, and GNS) were common among all four urinary signatures, and they were consistently excreted at higher rates in diabetes. Of the 13 proteins that were uniquely associated with our signature for early diabetes, we note that five had also been differentially excreted in the other studies ($P < 0.05$) but statistical significance was lost after multiple testing correction ($Q > 0.05$), suggesting that they may be differentially excreted in diabetes, but have a smaller overall effect size.

Forest plots were subsequently created to visualize fold changes and the degree of statistical significance of the four proteins selected for validation (Fig 5B). These proteins (CD14, HEXA, LUM, and VCAM-1) were not among the differentially excreted proteins identified by Magagnotti and colleagues. Urinary excretion of CD14, HEXA, and LUM was significantly elevated in early diabetes as reported by Singh and colleagues [24], but was variable in the study by Suh and colleagues [25]. We also examined the other proteins involved in keratan sulfate biology and degradation in the external studies and found that increased excretion of GALNS, GLB1, GNS, and HEXB was also reported by at least one other study (S3 Fig).

We also searched the Nephroseq v5 database (www.nephroseq.org, March 2020, University of Michigan, Ann Arbor, MI) for renal expression data of the urinary signature proteins. These transcriptomic datasets allow for a more comprehensive examination of genes dysregulated in various renal pathologies. Of the 34 signature proteins, 32 were differentially expressed with absolute fold changes above 2 (S7 Table). Expression of more than half of our signature proteins was markedly altered in datasets characterizing chronic kidney disease (with 27 proteins), diabetic nephropathy (with 21 proteins), and lupus (with 18 proteins). However, the direction of fold change was highly discordant in chronic kidney disease compared to our urinary expression levels, as 15 out of the 27 proteins with altered mRNA expression were mismatched. In contrast, we noted that only three proteins in diabetes and two in lupus were discordant. Of the 4 proteins selected for validation, we observed that CD14, lumican, and VCAM-1 are overexpressed in subsets characterizing diabetic nephropathy, focal segmental glomerulosclerosis, and lupus; however, our observed increases in HEXA urinary excretion was not reflected at the tissue level in Nephroseq as only two datasets reported significantly altered expression in opposing directions. Nevertheless, the overall findings demonstrate that mRNA levels of our signature proteins are altered at the tissue level in various etiologies of chronic kidney disease.

Discussion

Chronic exposure to high glucose results in several compensatory and maladaptive responses in the kidney. However, the mechanisms responsible for initiating diabetic kidney disease are poorly understood. This gap in knowledge may be, at least in part, responsible for the lack of effective treatment strategies that prevent, cure, or reverse diabetic kidney disease. In this
study, our goal was to examine the early effects of chronic hyperglycemia on the diabetic kidney. Using a discovery-based proteomic analysis of urine samples from otherwise healthy youths with and without type 1 diabetes, we identified a urinary signature of 34 proteins dominated by lysosomal enzymes. Additionally, these proteins are involved in neutrophil degranulation, the innate immunity, and keratan sulfate degradation. Increased urinary excretion of CD14, HEXA, and lumican was validated using ELISA assays in a second cohort. These candidates were also identified in other proteomic studies as potential indicators of early type 1 diabetes. Our findings suggest that lysosomal enzymes, glycosaminoglycan metabolism, and innate immunity may be perturbed in early diabetes before classic indications of clinical injury.

Urinary proteomics has been extensively employed to identify markers of progressive diabetic kidney disease. Much of the attention has been placed on later stages of disease, in which some degree of renal impairment is present [11]. Recent studies have instead shifted the spotlight on early diabetes before the development of microalbuminuria or glomerular filtration rate decline [24–26]. Notably, Suh and colleagues examined the urinary proteomes of youths with type 1 diabetes and included their non-diabetic siblings as healthy controls using filter-aided sample preparation [25]. Similar to our findings, lysosomal enzymes had emerged as important constituents in their urinary signature and were thought to indicate early inflammation in the renal vasculature [25]. Singh and colleagues also reported that youths with type 1 diabetes excreted higher amounts of lumican, CD14, and various lysosomal proteins such as ASAH1, CTSD, and NAGA compared to their non-diabetic siblings [24]. The authors speculated that these proteins may reflect changes in extracellular matrix [24]. In a multi-omics study, Magagnotti and colleagues first performed gel-based proteomic profiling of youths

Fig 5. Comparison of current findings with the literature. (A) Venn diagram of the urinary signature proteins from our current study (highlighted in red) and three other proteomic studies of early diabetes. Signature proteins were defined on the basis of statistical significance after Benjamini-Hochberg adjustment ($Q < 0.05$) for three studies [24, 25], including our analysis, or on the basis of a combination of factors ($|\text{fold change}| > 1.6, P < 0.06$) for the study by Magagnotti and colleagues [26]. (B) Forest plots of fold changes of urinary excretion of the four proteins selected for validation. Fold change is calculated as a ratio of the median excretion of youths with diabetes to that of youths without diabetes. Colours delineate proteins that belong to the urinary signature of the indicated study (red, $Q < 0.05$); proteins that were differentially excreted but lost statistical significance after Benjamini-Hochberg adjustment (purple, $P < 0.05$); and proteins that failed to reach statistical significance before and after adjustment (black, $P \geq 0.05$). CD14, monocyte differentiation antigen CD14; HEXA, beta-hexosaminidase subunit alpha; HC, non-diabetic youths; LUM, lumican; T1D, youths with type 1 diabetes; VCAM-1, vascular adhesion molecule-1.

https://doi.org/10.1371/journal.pone.0233639.g005
within 1 year of diagnosis of type 1 diabetes to establish an early predictive signature of kidney dysfunction [26]. Two lysosomal enzymes, ARSA and GLB1, were highlighted as part of the predictive profile for diabetic nephropathy. Various ceramides were subsequently examined by lipidomic profiling as downstream metabolites of ARSA and GLB1. The authors demonstrated that urinary levels of the lysosomal enzymes and ceramides were markedly increased in diabetic nephropathy. Interestingly, lysosomal enzymes have also been associated with other diabetic complications such as retinopathy, neurodegeneration, and microangiopathy [27–29]. Our analyses using Nephroseq datasets suggest that these enzymes are also overexpressed in renal tissues from individuals with chronic kidney disease, diabetic nephropathy, and lupus nephritis.

Even though the individual proteins differ between proteomic studies of early diabetes, the gene ontology terms that were overrepresented by the three published urinary signatures converge onto lysosomal enzymes [24–26]. According to our pathway analyses, the lysosomal enzymes are linked to neutrophil degranulation, innate immune system, and keratan sulfate degradation. Neutrophils are recruited to the site of injury as part of the early inflammatory phase of wound healing. Upon differentiation, these cells form granules containing hydrolytic enzymes and extracellular matrix components, which are functionally similar to lysosomes [30, 31]. Granules can mobilize to and fuse with the plasma membrane to release its secretory contents into the extracellular space and present its membrane contents onto the cell surface via exocytosis. Degranulation is one of the three main mechanisms by which neutrophils help clear pathogens [32]. Increased granule release has also been implicated in several autoimmune diseases such as asthma, lupus, and rheumatoid arthritis [33–35]. Although inflammation is often associated later stages of diabetic kidney disease, there is growing support for its early activation before clinical manifestations of kidney injury [36, 37]. We thus posit that increased urinary excretion of lysosomal enzymes may reflect an early activation of inflammation in response to chronic hyperglycemia.

Renal inflammation is a critical hallmark of diabetic kidney disease initiation and progression. Chronic hyperglycemia is known to disrupt the metabolic milieu inside the cell. The cell adapts by redirecting excess intracellular glucose into one of four hypothesized pathways: the polyol pathway, the formation of advanced glycation end-products, the protein kinase C signaling pathway, and the hexosamine pathway—all of which contribute to or reflect an increased production of reactive oxygen species. As a result, the primary initiating event in the development of diabetic complications is injury from oxidative stress [38–40]. Recent studies have also implicated the sterile, pathogen-free activation of toll-like receptors (TLRs), NFκB signaling, and the inflammasome, as part of the unresolved inflammatory response in the diabetic kidney [41–44]. In other words, TLR signalling can be triggered by damaged-associated molecular patterns (DAMPs) that are released by injured or stressed kidney cells [44, 45], thereby perpetuating the cycle of injury-inflammation response.

Keratan sulfate degradation is a natural turnover process that occurs in the lysosome. Remarkably, our urinary signature for early diabetes includes a core protein of the keratan sulfate proteoglycan (lumican) and the complete set of putative enzymes that break down keratan sulfate (GALNS, GLB1, GNS, HEXA, and HEXB), which were all excreted to a greater extent by youths with type 1 diabetes, compared to their non-diabetic peers and were strongly correlated with one another. Keratan sulfates consist of repeating disaccharide units of N-acetylgalactosamine and galactose (GlcNAc-Gal) [46]. As proteoglycans, keratan sulfates attach to either asparagine (N-linked) or serine/threonine (O-linked) residues of core proteins such as lumican, aggrecan, and fibromodulin. The glycosidic bonds are severed by GLB1, HEXA, HEXB to release the sugar monomers; the sulfates, by GALNS and GNS. The degree of sulfation varies and plays an important role in adhesion, as macrophages preferentially bind to lumican with
minimally sulfated keratan sulfate chains over intact forms [47]. Furthermore, the proteoglycan modulates the innate immune response, by interacting with the TLR4 co-receptor, CD14 [48, 49] and by facilitating neutrophil extravasation [50, 51]. Interestingly, TLR4 activation was highlighted as a potential mechanism in a genome-wide association study of diabetic kidney disease [52], linking keratan sulfate biology to inflammation. Lumican also regulates collagen fibril assembly and function [53] and contributes to wound healing [54, 55]. Although keratan sulfate proteoglycans are expressed throughout the body, they have been largely described in the cornea, brain, bone, and cartilage [46]. Previous studies have identified differences in lumican-based proteoglycan in healthy and diabetic kidney. In tumour-free tissues from otherwise healthy individuals undergoing nephrectomies for renal cell carcinoma, lumican-based proteoglycans were predominantly detected in the tubulointerstitium, deriving from peritubular mesenchymal cells, with a lower expression in the mesangial matrix of the glomerular compartments; in diabetic tissues, a marked increase in tubular expression was observed, which was not paralleled in glomeruli until advanced diabetic kidney disease was established [56, 57]. Additional experimental work is required to clarify whether increased urinary excretion of lysosomal enzymes may reflect a loss of enzymatic turnover activity in the kidney, thereby explaining the observed overexpression of lumican proteoglycans in diabetic kidney tissues.

Our study provides robust data that are consistent with and affirm previous findings, in which lysosomal perturbations may be at the forefront of the early diabetic kidney response. Dysregulated pathways in keratan sulfate metabolism have not previously been linked to early diabetes and represent a novel observation. We were also able to replicate increased urinary excretion of a select number of proteins in our internal validation cohort. Additionally, we performed an external validation by comparing our findings to other proteomic studies, despite differences in sample preparation and methodologies. Finally, our raw data and complete protein lists have been made publicly available.

Our study has limitations. First, we conducted a cross-sectional study and therefore cannot draw conclusions about cause-effect relationships between diabetes and changes in the urinary proteome. Our study nevertheless provides important preliminary data for future studies that will assess the clinical utility of these differentially excreted proteins in larger, more heterogeneous populations that include individuals with type 2 diabetes and at varying stages of diabetic kidney disease. Second, additional experimental work is required to examine the biology pertaining to keratan sulfate proteoglycans and lysosomal enzyme activity in the diabetic kidney before the onset of clinically-detectable disease. Advancements in single-cell transcriptomics and proteomics will enable us to pinpoint the exact origins of these urinary signature proteins and their potential localizations in nephron segments. Furthermore, in vitro and in vivo studies could also clarify whether chronic hyperglycemic conditions promote the lysosomal permeabilization and subsequent release of enzyme from kidneys and immune cells into urine and whether the shedding of lysosomal enzymes is associated with decreased intrarenal enzymatic activity and reduced turnover of proteoglycans. Third, our validation efforts were constrained by the limited availability of specific antibodies and ELISA kits, especially ones that have been designed and optimized for urinary measurements. A future goal would be to develop multiplexed targeted assays using selective or parallel reaction monitoring so that we can validate a more comprehensive set of lysosomal enzymes and protein targets.

Conclusions

In conclusion, we identified a urinary proteomic signature for early type 1 diabetes, of which lysosomal enzymes were major constituents. Our present findings suggest that lysosomal
enzymes, neutrophil degranulation, innate immunity, and keratan sulfate degradation may be involved in the early kidney response to hyperglycemia. Additional studies are needed to validate protein excretion in larger and broader populations and to elucidate the impact of lysosomal enzymes and keratan sulfate degradation in the diabetic kidney.

**Supporting information**

S1 Table. List of the 2313 quantified urinary proteins from the discovery cohort. (XLSX)

S2 Table. List of the 576 urinary proteins found in every urine sample from the discovery cohort. (XLSX)

S3 Table. Results from the pathDIP database using the 34 signature proteins. (XLSX)

S4 Table. Enriched KEGG pathways and functional hierarchies associated with the 34 signature proteins. (XLSX)

S5 Table. Enriched Reactome pathways associated with the 34 signature proteins. (XLSX)

S6 Table. Fold changes of the 34 signature proteins reported by other similarly designed published studies. (XLSX)

S7 Table. Fold Changes (FC) of the 34 signature proteins as reported by Nephroseq transcriptomic datasets comparing renal expression in individuals with varying kidney diseases to living or deceased donors. (XLSX)

S1 Fig. Correlogram of urinary excretion of the 34 signature proteins from the discovery cohort. Pearson correlations of log-transformed protein label-free quantification (LFQ) intensities are shown before the protein header. *P* values are shown above the header. (DOCX)

S2 Fig. Correlograms of urinary excretion of specific signature proteins. Pearson correlations of log-transformed protein intensities are shown before the protein header. *P* values are shown above the header. (A) Sub-analysis of the five enzymes associated with keratan sulfate degradation and lumican, a core protein of keratan sulfate. Data is from the discovery cohort. (B) Sub-analysis of the four proteins selected for internal validation and six urinary cytokines/chemokines. Data is from the validation cohort. (C) Sub-analysis of the four proteins selected for internal validation. Data is from the discovery cohort. (DOCX)

S3 Fig. Forest plots of fold changes of urinary excretion of the five enzymes associated with keratan sulfate degradation and lumican, a core protein of keratan sulfate proteoglycan. Fold change is calculated as a ratio of the median excretion of youths with diabetes to that of youths without diabetes. Colours delineate proteins that belong to the urinary signature of the indicated study (red, *Q* < 0.05); proteins that were differentially excreted but lost statistical significance after Benjamini-Hochberg adjustment (purple, *P* < 0.05); and proteins that failed to
reach statistical significance before and after adjustment (black, $P \geq 0.05$).

(DOCX)

Acknowledgments

Special thanks to Christine Kerr, Daryl Baquillos, Laura Motran, Harriet Georgas, Denis Dane-man, Verónica Talunay, and Antoninus Soosaipillai.

Author Contributions

Conceptualization: Julie A. D. Van, Eleftherios P. Diamandis, James W. Scholey, Ana Konvalinka.

Data curation: Julie A. D. Van.

Formal analysis: Julie A. D. Van, Anne-Christin Hauschild.

Funding acquisition: Yesmino Elia, Farid H. Mahmud, Etienne Sochett, James W. Scholey.

Investigation: Julie A. D. Van.

Methodology: Julie A. D. Van, Sergi Clotet-Freixas, Anne-Christin Hauschild, Ihor Batruch, Eleftherios P. Diamandis, James W. Scholey, Ana Konvalinka.

Project administration: Etienne Sochett.

Resources: Yesmino Elia, Farid H. Mahmud, Eleftherios P. Diamandis.

Software: Igor Jurisica.

Supervision: James W. Scholey.

Validation: Julie A. D. Van.

Visualization: Julie A. D. Van.

Writing – original draft: Julie A. D. Van, James W. Scholey, Ana Konvalinka.

Writing – review & editing: Julie A. D. Van, Sergi Clotet-Freixas, Anne-Christin Hauschild, Ihor Batruch, Igor Jurisica, Yesmino Elia, Farid H. Mahmud, Etienne Sochett, Eleftherios P. Diamandis, James W. Scholey, Ana Konvalinka.

References

1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984; 310: 356–60. https://doi.org/10.1056/NEJM198402093100605 PMID: 6690964

2. Viberti GC, Keen H. Microalbuminuria and diabetes. Lancet. 1983; 1: 352. Available: http://www.ncbi.nlm.nih.gov/pubmed/6130350

3. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007; 18: 1353–61. https://doi.org/10.1681/ASN.2006080872 PMID: 17329575

4. Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014; 37: 226–34. https://doi.org/10.2337/dc13-0985 PMID: 23939543

5. Schultz CJ, Konopelska-Bahu T, Dalton RN, Carroll TA, Stratton I, Gale EA, et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care. 1999; 22: 495–502. Available: https://doi.org/10.2337/diacare.22.3.495 PMID: 10097935
6. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003; 348: 2285–93. https://doi.org/10.1056/NEJMoa021835 PMID: 12788992

7. Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashihagi A, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes. 2005; 54: 2983–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/16186402 https://doi.org/10.2337/diabetes.54.10.2983 PMID: 16186402

8. Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int. 1994; 45: 612–22. Available: http://www.ncbi.nlm.nih.gov/pubmed/8164451 https://doi.org/10.1038/ki.1994.80 PMID: 8164451

9. Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer SM. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med. 1989; 320: 966–70. https://doi.org/10.1056/NEJM198904133201503 PMID: 2784542

10. Mogensen CE, Christensen CK, Vittinghus E. The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy. Diabetes. 1983; 32 Suppl 2: 64–78. https://doi.org/10.2337/diabetes.32.2.S64 PMID: 6400670

11. Van JAD, Scholey JW, Konvalinka A. Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics. J Am Soc Nephrol. 2017; 28: 1050–1061. https://doi.org/10.1681/ASN.2016091018 PMID: 28159781

12. Di Meo A, Batruch I, Yousef AG, Pasic MD, Diamandis EP, Yousef GM. An integrated proteomic and peptidomic assessment of the normal human urine. Clin Chem Lab Med. 2017; 55: 237–247. https://doi.org/10.1515/cclm-2016-0390 PMID: 27394047

13. Van JAD, Clotet-freixas S, Zhou J, Batruch I, Sun C, Glogauer M, et al. Peptidomic analysis of urine from youths with early type 1 diabetes reveals novel bioactivity of uromodulin peptides in vitro. Mol Cell Proteomics. 2019; mcp.RA119.001858. https://doi.org/10.1074/mcp.RA119.001858 PMID: 31879271

14. Yamamoto T. The 4th Human Kidney and Urine Proteome Project (HKUPP) workshop. 26 September 2009, Toronto, Canada. Proteomics. 2010; 10: 2069–70. https://doi.org/10.1002/pmic.201090041 PMID: 20514649

15. Vizcaíno JA, Deutsch EW, Wang R, Csordas A, Reisinger F, Rios D, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol. 2014; 32: 223–226. https://doi.org/10.1038/nbt.2839 PMID: 24727771

16. Cox J, Neuhaus N, Michalski A, Scheltema RA, Olsen J V, Mann M. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011; 10: 1794–805. https://doi.org/10.1021/pr101065j PMID: 21254760

17. Tyanova S, Temu T, Sinicyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016; 13: 731–740. https://doi.org/10.1038/nmeth.3901 PMID: 27348712

18. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010; 28: 1248–50. https://doi.org/10.1038/nbt1210-1248 PMID: 21139605

19. Rahmati S, Abovsky M, Pastrello C, Kotlyar M, Lu R, Cumbaa CA, et al. pathDIP 4: an extended pathway annotations and enrichment analysis resource for human, model organisms and domesticated species. Nucleic Acids Res. 2020; 48: D479–D488. https://doi.org/10.1093/nar/gkz989 PMID: 31733064

20. Kanehisa M, Sato Y. KEGG Mapper for inferring cellular functions from protein sequences. Protein Sci. 2020; 29: 28–35. https://doi.org/10.1002/pro.3711 PMID: 31423653

21. Fabregat A, Jupe S, Matthews L, Sidropoulos K, Gillespie M, Garapati P, et al. The Reactome Pathway Knowledgebase. Nucleic Acids Res. 2018; 46: D649–D655. https://doi.org/10.1093/nar/gkx1132 PMID: 29145629

22. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2019; 48: D498–D503. https://doi.org/10.1093/nar/gkz1031 PMID: 31691815

23. Kotlyar M, Pastrello C, Malik Z, Jurisica I. IID 2018 update: context-specific physical protein-protein interactions in human, model organisms and domesticated species. Nucleic Acids Res. 2019; 47: D581–D589. https://doi.org/10.1093/nar/gky1037 PMID: 30407591

24. Singh H, Yu Y, Suh M-J, Torralba MG, Stenzel RD, Tovchigrechko A, et al. Type 1 Diabetes: Urinary Proteomics and Protein Network Analysis Support Perturbation of Lysosomal Function. Theranostics. 2017; 7: 2704–2717. https://doi.org/10.7150/thno.19679 PMID: 28819457
25. Suh M-J, Tovchigrechko A, Thovarai V, Rolfe MA, Torralba MG, Wang J, et al. Quantitative Differences in the Urinary Proteome of Siblings Discordant for Type 1 Diabetes Include Lysosomal Enzymes. J Proteome Res. 2015; 14: 3123–35. https://doi.org/10.1021/acs.jproteome.5b00052 PMID: 26143644

26. Magagnotti C, Zerbini G, Fermo I, Carletti RM, Bonfanti R, Vallone F, et al. Identification of nephropathy predictors in urine from children with a recent diagnosis of type 1 diabetes. J Proteomics. 2019; 193: 205–216. https://doi.org/10.1016/j.jprot.2018.10.010 PMID: 30366120

27. Caseiro A, Barros A, Ferreira R, Padrão A, Aroso M, Quintaneiro C, et al. Pursuing type 1 diabetes mellitus and related complications through urinary proteomics. Transl Res. 2014; 163: 188–199. https://doi.org/10.1016/j.trsl.2013.09.005 PMID: 24096133

28. Sims-Robinson C, Bakeman A, Rosko A, Glasser R, Feldman EL. The Role of Oxidized Cholesterol in Diabetes-Induced Lysosomal Dysfunction in the Brain. Mol Neurobiol. 2016; 53: 2287–2296. https://doi.org/10.1007/s12035-015-9207-1 PMID: 25976368

29. Waters PJ, Flynn MD, Corrall RJ, Pennock CA. Increases in plasma lysosomal enzymes in type 1 (insulin-dependent) diabetes mellitus: relationship to diabetic complications and glycaemic control. Diabetologia. 1992; 35: 991–5. https://doi.org/10.1007/BF00401431 PMID: 1451959

30. Dell’Angelica EC, Mullins C, Caplan S, Bonifacino JS. Lysosome-associated membrane proteins but retain the mannose 6-phosphate recognition marker. Blood. 1998; 91: 1044–58. Available: http://www.ncbi.nlm.nih.gov/pubmed/9446668 PMID: 9446668

31. Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? Front Physiol. 2017; 8. https://doi.org/10.3389/fphys.2016.00113 PMID: 29515456

32. Lacy P. Mechanisms of Degranulation in Neutrophils. Allergy, Asthma Clin Immunol. 2006; 2: 98. https://doi.org/10.1186/1710-1492-2-3-98 PMID: 20525154

33. Abramson SB, Given WP, Edelson HS, Weissmann G. Neutrophil aggregation induced by sera from patients with active systemic lupus erythematosus. Arthritis Rheum. 1983; 26: 630–6. https://doi.org/10.1002/art.1780260509 PMID: 6847725

34. Pillinger MH, Abramson SB. The neutrophil in rheumatoid arthritis. Rheum Dis Clin North Am. 1995; 21: 691–714. Available: http://www.ncbi.nlm.nih.gov/pubmed/8619095 PMID: 8619095

35. Har RLH, Reich HN, Scholey JW, Daneman D, Dunger DB, Moineddin R, et al. The urinary cytokine/chemokine signature of renal hyperfiltration in adolescents with type 1 diabetes. PLoS One. 2014; 9: e111131. https://doi.org/10.1371/journal.pone.0111131 PMID: 25392936

36. Cherney DZI, Scholey JW, Sochett E, Bradley TJ, Reich HN. The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes: a pilot study. Diabetes Care. 2011; 34: 177–80. https://doi.org/10.2337/dc10-1219 PMID: 20841614

37. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014; 124: 2333–2340. https://doi.org/10.1172/JCI72271 PMID: 24892707

38. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813–820. https://doi.org/10.1038/418413a PMID: 11742414

39. Brasacchio D, Okabe J, Tikelis C, Balcerczyk A, George P, Baker EK, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009; 58: 1229–36. https://doi.org/10.2337/db08-1666 PMID: 19208907

40. Hall RLH, Reich HN, Scholey JW, Komabhaskar SK, Draxler K, et al. Azurophilic granules of human neutrophilic leukocytes are deficient in lysosome-associated membrane proteins but retain the mannose 6-phosphate recognition marker. Blood. 1998; 91: 1044–58. Available: http://www.ncbi.nlm.nih.gov/pubmed/9446668 PMID: 9446668

41. Funderburgh JL. Keratan sulfate: structure, biosynthesis, and function. Glycobiochemistry. 2000; 10: 951–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/11030741 https://doi.org/10.1093/glycob/10.10.951 PMID: 11030741
47. Funderburgh JL, Mitschler RR, Funderburgh ML, Roth MR, Chapes SK, Conrad GW. Macrophage receptors for lumican. A corneal keratan sulfate proteoglycan. Invest Ophthalmol Vis Sci. 1997; 38: 1159–67. Available: http://www.ncbi.nlm.nih.gov/pubmed/9152235 PMID: 9152235

48. Wu F, Vij N, Roberts L, Lopez-Bromes S, Joyce S, Chakravarti S. A Novel Role of the Lumican Core Protein in Bacterial Lipopolysaccharide-induced Innate Immune Response. J Biol Chem. 2007; 282: 26409–26417. https://doi.org/10.1074/jbc.M702402200 PMID: 17616530

49. Shao H, Lee S, Gae-Scott S, Nakata C, Chen S, Hamad AR, et al. Extracellular Matrix Lumican Promotes Bacterial Phagocytosis, and Lumican Mice Show Increased Pseudomonas aeruginosa Lung Infection Severity. J Biol Chem. 2012; 287: 35860–35872. https://doi.org/10.1074/jbc.M112.380550 PMID: 22865855

50. Hayashi Y, Call MK, Chikama T-i, Liu H, Carlson EC, Sun Y, et al. Lumican is required for neutrophil extravasation following corneal injury and wound healing. J Cell Sci. 2010; 123: 2987–2995. https://doi.org/10.1242/jcs.068221 PMID: 20699360

51. Carlson EC, Lin M, Liu C-Y, Kao WW-Y, Perez VL, Pearlman E. Keratocan and lumican regulate neutrophil infiltration and corneal clarity in lipopolysaccharide-induced keratitis by direct interaction with CXCL1. J Biol Chem. 2007; 282: 35502–9. https://doi.org/10.1074/jbc.M705823200 PMID: 17911102

52. Salem RM, Todd JN, Sandholm N, Cole JB, Chen W-M, Andrews D, et al. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. J Am Soc Nephrol. 2019; 30: 2000–2016. https://doi.org/10.1681/ASN.2019030218 PMID: 31537649

53. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol. 1998; 141: 1277–86. https://doi.org/10.1083/jcb.141.5.1277 PMID: 9606218

54. Saika S, Shiraishi A, Saika S, Liu C-Y, Funderburgh JL, Kao CW-C, et al. Role of Lumican in the Corneal Epithelium during Wound Healing. J Biol Chem. 2000; 275: 2607–2612. https://doi.org/10.1074/jbc.275.4.2607 PMID: 10644720

55. Liu X-J, Kong F-Z, Wang Y-H, Zheng J-H, Wan W-D, Deng C-L, et al. Lumican Accelerates Wound Healing by Enhancing α2β1 Integrin-Mediated Fibroblast Contractility. Zhou Z, editor. PLoS One. 2013; 8: e67124. https://doi.org/10.1371/journal.pone.0067124 PMID: 23840601

56. Schaefer L, Gröne H-J, Raslik I, Robeneck H, Ugorcakova J, Budny S, et al. Small proteoglycans of normal adult human kidney: Distinct expression patterns of decorin, biglycan, fibromodulin, and lumican. Kidney Int. 2000; 58: 1557–1568. https://doi.org/10.1046/j.1523-1755.2000.00317.x PMID: 11012890

57. Schaefer L, Raslik I, Gröne H-J, Schonherr E, Macakova K, Ugorcakova J, et al. Small proteoglycans in human diabetic nephropathy: Discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. FASEB J. 2001; 15: 559–561. https://doi.org/10.1096/fj.00-4933fje PMID: 11259366